Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Pharmacokinetics and Pharmacodynamics of Anti-infective Agents during Continuous Veno-venous Hemofiltration in Critically Ill Patients: Lessons Learned from an Ancillary Study of the IVOIRE Trial.

Breilh D, Honore PM, De Bels D, Roberts JA, Gordien JB, Fleureau C, Dewitte A, Coquin J, Rozé H, Perez P, Attou R, Redant S, Kugener L, Saux MC, Spapen HD, Ouattara A, Joannes-Boyau O; IVOIRE study group.

J Transl Int Med. 2019 Dec 31;7(4):155-169. doi: 10.2478/jtim-2019-0031. eCollection 2019 Dec.

2.

Are standard dosing regimens of Amikacin suitable in Critically Ill Patients with Open Abdomen and Negative Pressure Wound Therapy? A population pharmacokinetic study.

Carrié C, Delzor F, Roure S, Dubuisson V, Petit L, Molimard M, Breilh D, Biais M.

Antimicrob Agents Chemother. 2020 Jan 21. pii: AAC.02098-19. doi: 10.1128/AAC.02098-19. [Epub ahead of print]

PMID:
31964795
3.

Implementation of infliximab standardized doses after pharmacokinetic modelization in a cohort of patients with Crohn's disease.

Poullenot F, Ollivier J, Rivière P, Sauvaget L, Berroneau A, Djabarouti S, Xuereb F, Zerbib F, Breilh D, Laharie D.

Dig Liver Dis. 2019 Dec 21. pii: S1590-8658(19)30927-2. doi: 10.1016/j.dld.2019.11.018. [Epub ahead of print]

PMID:
31874834
4.

Is the subcutaneous route an alternative for administering ertapenem to older patients? PHACINERTA study.

Roubaud Baudron C, Legeron R, Ollivier J, Bonnet F, Greib C, Guerville F, Cazanave C, Kobeh D, Cressot V, Moneger N, Videau MN, Thiel E, Foucaud C, Lafargue A, de Thezy A, Durrieu J, Bourdel Marchasson I, Pinganaud G, Breilh D.

J Antimicrob Chemother. 2019 Dec 1;74(12):3546-3554. doi: 10.1093/jac/dkz385.

PMID:
31730164
5.

Are Standard Dosing Regimens of Ceftriaxone Adapted for Critically Ill Patients with Augmented Creatinine Clearance?

Ollivier J, Carrié C, d'Houdain N, Djabarouti S, Petit L, Xuereb F, Legeron R, Biais M, Breilh D.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e02134-18. doi: 10.1128/AAC.02134-18. Print 2019 Mar.

6.

Higher than standard dosing regimen are needed to achieve optimal antibiotic exposure in critically ill patients with augmented renal clearance receiving piperacillin-tazobactam administered by continuous infusion.

Carrié C, Legeron R, Petit L, Ollivier J, Cottenceau V, d'Houdain N, Boyer P, Lafitte M, Xuereb F, Sztark F, Breilh D, Biais M.

J Crit Care. 2018 Dec;48:66-71. doi: 10.1016/j.jcrc.2018.08.026. Epub 2018 Aug 23.

PMID:
30172963
7.
8.

Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis.

Calmettes C, Gabriel F, Blanchard E, Servant V, Bouchet S, Kabore N, Forcade E, Leroyer C, Bidet A, Latrabe V, Leguay T, Vigouroux S, Tabrizi R, Breilh D, Accoceberry I, de Lara MT, Pigneux A, Milpied N, Dumas PY.

Oncotarget. 2018 Jun 1;9(42):26724-26736. doi: 10.18632/oncotarget.25477. eCollection 2018 Jun 1.

9.

French hospital discharge database (PMSI) and bacterial resistance: Is coding adapted to hospital epidemiology?

de Léotoing L, Barbier F, Dinh A, Breilh D, Chaize G, Vainchtock A, Levy-Bachelot L, Bensoussan C, Dramard S, Fernandes J.

Med Mal Infect. 2018 Oct;48(7):465-473. doi: 10.1016/j.medmal.2018.03.007. Epub 2018 Apr 17.

PMID:
29673880
10.

Association between augmented renal clearance, antibiotic exposure and clinical outcome in critically ill septic patients receiving high doses of β-lactams administered by continuous infusion: a prospective observational study.

Carrié C, Petit L, d'Houdain N, Sauvage N, Cottenceau V, Lafitte M, Foumenteze C, Hisz Q, Menu D, Legeron R, Breilh D, Sztark F.

Int J Antimicrob Agents. 2018 Mar;51(3):443-449. doi: 10.1016/j.ijantimicag.2017.11.013. Epub 2017 Nov 24.

PMID:
29180280
11.

A new reliable, transposable and cost-effective assay for absolute quantification of total plasmatic bevacizumab by LC-MS/MS in human plasma comparing two internal standard calibration approaches.

Legeron R, Xuereb F, Chaignepain S, Gadeau AP, Claverol S, Dupuy JW, Djabarouti S, Couffinhal T, Schmitter JM, Breilh D.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Dec 1;1070:43-53. doi: 10.1016/j.jchromb.2017.10.042. Epub 2017 Oct 23.

PMID:
29111437
12.

Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Severely Obese Versus Nonobese Critically Ill Septic Patients and the Risk of Under- and Overdosing.

Jung B, Mahul M, Breilh D, Legeron R, Signe J, Jean-Pierre H, Uhlemann AC, Molinari N, Jaber S.

Crit Care Med. 2017 May;45(5):e470-e478. doi: 10.1097/CCM.0000000000002287.

PMID:
28240688
13.

Pre-dose plasma concentration monitoring of mycophenolate mofetil in patients with autoimmune diseases.

Streicher C, Djabarouti S, Xuereb F, Lazaro E, Legeron R, Bouchet S, Greib C, Breilh D, Pellegrin JL, Viallard JF.

Br J Clin Pharmacol. 2014 Dec;78(6):1419-25. doi: 10.1111/bcp.12462.

14.

In vivo interactions of continuous flucloxacillin infusion and high-dose oral rifampicin in the serum of 15 patients with bone and soft tissue infections due to Staphylococcus aureus - a methodological and pilot study.

Garzoni C, Uçkay I, Belaieff W, Breilh D, Suvà D, Huggler E, Lew D, Hoffmeyer P, Bernard L.

Springerplus. 2014 Jun 7;3:287. doi: 10.1186/2193-1801-3-287. eCollection 2014.

15.

Chemical stability of azacitidine suspensions for injection after cold-chain reconstitution of powder and storage.

Legeron R, Xuereb F, Djabarouti S, Saux MC, Breilh D.

Am J Health Syst Pharm. 2013 Dec 1;70(23):2137-42. doi: 10.2146/ajhp120372.

PMID:
24249764
16.

Carbapenems.

Breilh D, Texier-Maugein J, Allaouchiche B, Saux MC, Boselli E.

J Chemother. 2013 Feb;25(1):1-17. doi: 10.1179/1973947812Y.0000000032. Review.

PMID:
23433439
17.

Lower 12-hour trough concentrations of mycophenolic acid in patients with active systemic vasculitides taking mycophenolate mofetil.

Djabarouti S, Lazaro E, Breilh D, Pellegrin JL, Viallard JF.

J Rheumatol. 2012 Nov;39(11):2222-3. doi: 10.3899/jrheum.120606. No abstract available.

PMID:
23118295
18.

Alveolar diffusion and pharmacokinetics of linezolid administered in continuous infusion to critically ill patients with ventilator-associated pneumonia.

Boselli E, Breilh D, Caillault-Sergent A, Djabarouti S, Guillaume C, Xuereb F, Bouvet L, Rimmelé T, Saux MC, Allaouchiche B.

J Antimicrob Chemother. 2012 May;67(5):1207-10. doi: 10.1093/jac/dks022. Epub 2012 Feb 20.

PMID:
22351682
19.

A sensitive liquid chromatography coupled with mass spectrometry method for the intracellular and plasma quantification of raltegravir after solid-phase extraction.

Mosnier-Thoumas S, Djabarouti S, Xuereb F, Lazaro E, Pellegrin JL, Saux MC, Breilh D.

J Pharm Pharmacol. 2011 Dec;63(12):1559-65. doi: 10.1111/j.2042-7158.2011.01368.x.

PMID:
22060286
20.

Chemotherapy and targeted agents for colorectal cancer in a real-life setting anticipate guidelines: the COLCHIC cohort study.

Smith D, Terrebonne E, Rouyer M, Blanc JF, Breilh D, Pedeboscq S, Le Monies A, Lecomte C, Lassalle R, Moore N, Fourrier-Réglat A.

Fundam Clin Pharmacol. 2013 Feb;27(1):113-9. doi: 10.1111/j.1472-8206.2011.00961.x. Epub 2011 Jul 27.

PMID:
21793898
21.

Pharmacokinetics of free ertapenem in critically ill septic patients: intermittent versus continuous infusion.

Breilh D, Fleureau C, Gordien JB, Joanes-Boyau O, Texier-Maugein J, Rapaport S, Boselli E, Janvier G, Saux MC.

Minerva Anestesiol. 2011 Nov;77(11):1058-62. Epub 2011 May 11.

22.

Quantitative analysis of erythropoietin in human plasma by tandem mass spectrometry.

Xuereb F, Chaignepain S, Breilh D, Godde F, Saux MC, Lenz C, Glueckmann M, Schmitter JM.

Anal Bioanal Chem. 2011 Jun;400(7):2073-84. doi: 10.1007/s00216-011-4897-3. Epub 2011 Mar 29.

PMID:
21445661
23.

Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study.

Djabarouti S, Breilh D, Duffau P, Lazaro E, Greib C, Caubet O, Saux MC, Pellegrin JL, Viallard JF.

Arthritis Res Ther. 2010;12(6):R217. doi: 10.1186/ar3202. Epub 2010 Dec 22. Erratum in: Arthritis Res Ther. 2011;13(2):401.

24.

An in vitro study of epoetin beta intravenous injection site at the end of hemodialysis.

Xuereb F, de Précigout V, Combe C, Sinnasse-Raymond G, Saux MC, Breilh D.

Int J Pharm. 2010 Aug 30;396(1-2):140-2. doi: 10.1016/j.ijpharm.2010.06.010. Epub 2010 Jun 11.

PMID:
20542102
25.

HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.

da Silva D, Van Wesenbeeck L, Breilh D, Reigadas S, Anies G, Van Baelen K, Morlat P, Neau D, Dupon M, Wittkop L, Fleury H, Masquelier B.

J Antimicrob Chemother. 2010 Jun;65(6):1262-9. doi: 10.1093/jac/dkq099. Epub 2010 Apr 12.

PMID:
20388636
26.

Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus.

Djabarouti S, Duffau P, Lazaro E, Chapouly C, Greib C, Viallard JF, Pellegrin JL, Saux MC, Breilh D.

Expert Opin Pharmacother. 2010 Apr;11(5):689-99. doi: 10.1517/14656561003592144.

PMID:
20210680
27.

Ribavirin plasma concentration predicts sustained virological response to peginterferon Alfa 2a plus ribavirin in previously treated HCV-HIV-coinfected patients.

Breilh D, Djabarouti S, Trimoulet P, Le Bail B, Dupon M, Ragnaud JM, Fleury H, Saux MC, Thiébaut R, Chêne G, Neau D.

J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):428-30. doi: 10.1097/QAI.0b013e3181b62858. No abstract available.

PMID:
19858925
28.

Simultaneous determination of five systemic azoles in plasma by high-performance liquid chromatography with ultraviolet detection.

Gordien JB, Pigneux A, Vigouroux S, Tabrizi R, Accoceberry I, Bernadou JM, Rouault A, Saux MC, Breilh D.

J Pharm Biomed Anal. 2009 Dec 5;50(5):932-8. doi: 10.1016/j.jpba.2009.06.030. Epub 2009 Jun 24.

PMID:
19608374
29.

Toxicokinetics of voriconazole during massive intentional poisoning.

Rozé H, Lafargue M, Joannes-Boyau O, Batoz H, Dromer C, Breilh D, Janvier G.

J Antimicrob Chemother. 2009 Sep;64(3):662-3. doi: 10.1093/jac/dkp219. Epub 2009 Jun 17. No abstract available.

PMID:
19535384
30.

Impact of ribavirin plasma level on sustained virological response in patients treated with pegylated interferon and ribavirin for chronic hepatitis C.

Breilh D, Foucher J, Castéra L, Trimoulet P, Djabarouti S, Merrouche W, Couzigou P, Saux MC, de Lédinghen V.

Aliment Pharmacol Ther. 2009 Sep 1;30(5):487-94. doi: 10.1111/j.1365-2036.2009.04065.x. Epub 2009 Jun 11.

31.

Quantitative and qualitative control of cytotoxic preparations by HPLC-UV in a centralized parenteral preparations unit.

Delmas A, Gordien JB, Bernadou JM, Roudaut M, Gresser A, Malki L, Saux MC, Breilh D.

J Pharm Biomed Anal. 2009 Jul 12;49(5):1213-20. doi: 10.1016/j.jpba.2009.03.007. Epub 2009 Mar 20.

PMID:
19362442
32.

Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort.

Wittkop L, Breilh D, Da Silva D, Duffau P, Mercié P, Raymond I, Anies G, Fleury H, Saux MC, Dabis F, Fagard C, Thiébaut R, Masquelier B, Pellegrin I; ANRS CO3 Aquitaine Cohort.

J Antimicrob Chemother. 2009 Jun;63(6):1251-5. doi: 10.1093/jac/dkp114. Epub 2009 Mar 31.

33.

Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy.

Wittkop L, Commenges D, Pellegrin I, Breilh D, Neau D, Lacoste D, Pellegrin JL, Chêne G, Dabis F, Thiébaut R.

BMC Med Res Methodol. 2008 Oct 22;8:68. doi: 10.1186/1471-2288-8-68.

34.

Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).

Pellegrin I, Wittkop L, Joubert LM, Neau D, Bollens D, Bonarek M, Girard PM, Fleury H, Winters B, Saux MC, Pellegrin JL, Thiébaut R, Breilh D; ANRS Co3 Aquitaine Cohort.

Antivir Ther. 2008;13(2):271-9.

PMID:
18505178
35.

Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia.

Boselli E, Breilh D, Rimmelé T, Guillaume C, Xuereb F, Saux MC, Bouvet L, Chassard D, Allaouchiche B.

Crit Care Med. 2008 May;36(5):1500-6. doi: 10.1097/CCM.0b013e318170ba21.

PMID:
18434883
36.

Diffusion of ertapenem into bone and synovial tissues.

Boselli E, Breilh D, Djabarouti S, Bel JC, Saux MC, Allaouchiche B.

J Antimicrob Chemother. 2007 Oct;60(4):893-6. Epub 2007 Aug 17.

PMID:
17704514
37.

Reliability of mini-bronchoalveolar lavage for the measurement of epithelial lining fluid concentrations of tobramycin in critically ill patients.

Boselli E, Breilh D, Djabarouti S, Guillaume C, Rimmelé T, Gordien JB, Xuereb F, Saux MC, Allaouchiche B.

Intensive Care Med. 2007 Sep;33(9):1519-23. Epub 2007 May 25.

PMID:
17530217
38.

Pravastatin in HIV-infected patients treated with protease inhibitors: a placebo-controlled randomized study.

Bonnet F, Aurillac-Lavignolle V, Breilh D, Thiébaut R, Peuchant E, Bernard N, Lacoste D, Dabis F, Beylot J, Chêne G, Morlat P; GECSA.

HIV Clin Trials. 2007 Jan-Feb;8(1):53-60.

PMID:
17434849
39.

Efficacy and tolerance of high-dose inhaled ipratropium bromide vs. terbutaline in intubated premature human neonates.

Fayon M, Tayara N, Germain C, Choukroun ML, De La Roque ED, Chêne G, Breilh D, Marthan R, Demarquez JL.

Neonatology. 2007;91(3):167-73. Epub 2006 Nov 29.

PMID:
17377401
40.

Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients.

Pellegrin I, Breilh D, Coureau G, Boucher S, Neau D, Merel P, Lacoste D, Fleury H, Saux MC, Pellegrin JL, Lazaro E, Dabis F, Thiébaut R; ANRS Co3 Aquitaine Cohort.

Antimicrob Agents Chemother. 2007 Apr;51(4):1473-80. Epub 2007 Feb 12.

41.

Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia.

Boselli E, Breilh D, Saux MC, Gordien JB, Allaouchiche B.

Intensive Care Med. 2006 Dec;32(12):2059-62. Epub 2006 Oct 13.

PMID:
17039351
42.

Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study).

Djabarouti S, Breilh D, Pellegrin I, Lavit M, Camou F, Caubet O, Fleury H, Saux MC, Pellegrin JL.

J Antimicrob Chemother. 2006 Nov;58(5):1090-3. Epub 2006 Aug 18.

PMID:
16921181
43.

Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).

Pellegrin I, Breilh D, Ragnaud JM, Boucher S, Neau D, Fleury H, Schrive MH, Saux MC, Pellegrin JL, Lazaro E, Vray M.

Antivir Ther. 2006;11(4):421-9.

PMID:
16856615
44.

Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumonia.

Mimoz O, Rolland D, Adoun M, Marchand S, Breilh D, Brumpt I, Debaene B, Couet W.

Intensive Care Med. 2006 May;32(5):775-9. Epub 2006 Mar 21.

PMID:
16550370
45.

Determination of free ertapenem in plasma and bronchoalveolar lavage by high-performance liquid chromatography with ultraviolet detection.

Gordien JB, Boselli E, Fleureau C, Allaouchiche B, Janvier G, Lalaude O, Saux MC, Breilh D.

J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Jan 18;830(2):218-23. Epub 2005 Nov 14.

PMID:
16290251
46.

Low amounts of trans 18:1 fatty acids elevate plasma triacylglycerols but not cholesterol and alter the cellular defence to oxidative stress in mice.

Cassagno N, Palos-Pinto A, Costet P, Breilh D, Darmon M, Bérard AM.

Br J Nutr. 2005 Sep;94(3):346-52.

PMID:
16176604
47.

Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia.

Boselli E, Breilh D, Rimmelé T, Djabarouti S, Toutain J, Chassard D, Saux MC, Allaouchiche B.

Crit Care Med. 2005 Jul;33(7):1529-33.

PMID:
16003058
48.

Site specific alterations of adipose tissue mitochondria in 3'-azido-3'-deoxythymidine (AZT)-treated rats: an early stage in lipodystrophy?

Deveaud C, Beauvoit B, Hagry S, Galinier A, Carrière A, Salin B, Schaeffer J, Caspar-Bauguil S, Fernandez Y, Gordien JB, Breilh D, Penicaud L, Casteilla L, Rigoulet M.

Biochem Pharmacol. 2005 Jul 1;70(1):90-101.

PMID:
15894294
49.

Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia.

Boselli E, Breilh D, Rimmelé T, Djabarouti S, Saux MC, Chassard D, Allaouchiche B.

Crit Care Med. 2005 Jan;33(1):104-9.

PMID:
15644655
50.

Simultaneous determination of the antiretroviral agents: amprenavir, lopinavir, ritonavir, saquinavir and efavirenz in human peripheral blood mononuclear cells by high-performance liquid chromatography-mass spectrometry.

Rouzes A, Berthoin K, Xuereb F, Djabarouti S, Pellegrin I, Pellegrin JL, Coupet AC, Augagneur S, Budzinski H, Saux MC, Breilh D.

J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Dec 25;813(1-2):209-16.

PMID:
15556535

Supplemental Content

Loading ...
Support Center